Expertise in
6
conditions

Karin Kast

Kerpener Str. 62, 
Koeln, NW, DE 
Expertise in
6
conditions
Kerpener Str. 62, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Karin Kast practices in Koeln, Germany. Ms. Kast is highly rated in 6 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Breast Cancer, Li-Fraumeni Syndrome, Salpingo-Oophorectomy, and Oophorectomy.

Her clinical research consists of co-authoring 92 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Kerpener Str. 62, Koeln, NW 50937, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Pazopanib Vs. Pazopanib Plus Gemcitabine in Patients with Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Pazopanib Vs. Pazopanib Plus Gemcitabine in Patients with Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -
Enrollment Status: Active_not_recruiting
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drugs: Pazopanib, Gemcitabine
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer
A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: February 23, 2022
Intervention Type: Drug
Study Drugs: Everolimus, Standard Care
Study Phase: Phase 2
View 1 Less Clinical Trial

92 Total Publications

Breast Density Changes after Risk-Reducing Salpingo-oophorectomy in Women with a Pathogenic Germline Variant in BRCA1 or BRCA2.
Breast Density Changes after Risk-Reducing Salpingo-oophorectomy in Women with a Pathogenic Germline Variant in BRCA1 or BRCA2.
Journal: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Published: February 14, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Kast's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile